ctDNA and MRD: Who, When, and Then What? | 2022 Evolution Conference

We begin this focused oncology session with a discussion of circulating tumor DNA (ctDNA) as a means to detect minimal residual disease (MRD) in cancer patients. Dr Aparna Parikh from Massachusetts General Hospital discusses the three major unresolved questions surrounding the use of ctDNA technology to detect MRD - the who, the when, and probably most importantly, the ‘then what?’ To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.